April 29th 2025
The agency's decision was based on data from the phase 3 VIITAL study (NCT04227106).
Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 66th ASH Annual Meeting
April 26-27, 2025
Register Now!
29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
28th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
View More
New Combination-Based Approaches to Newly Diagnosed MM: What Do the Data, the Experts, and Patients Say?
View More
Medical Crossfire®: Onco-Nurses Exchange Best Practices on PNH Treatment and Symptom Management Along the Patient Care Journey
View More
Show Me Your Care Plan™: How Can Onco-Nurses Improve Patient Care in CML Across the Treatment Continuum?
View More
Show Me Your Care Plan! Managing Breast Cancer Patients Under Current Data for Immuno- and Targeted Therapies, CDK4/6i, ADCs and Beyond
View More
OPMD and Advancements in Genetic Research
April 22nd 2025Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio, discussed the genetic basis of oculopharyngeal muscular dystrophy, as well as the primary challenges in diagnosing and treating the condition.
Matthew Wicklund, MD, on OPMD and Advancements in Genetic Research
April 13th 2025The professor of neurology at the University of Texas Health Science Center San Antonio discussed the genetic basis of oculopharyngeal muscular dystrophy, as well as the primary challenges in diagnosing and treating the condition.